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Purpose or Objective 
Recommendations for surveillance after stereotactic body 
radiation therapy (SBRT) for early stage non–small cell lung 
cancer (NSCLC) are not well defined. Recently, PET response 
criteria in solid tumors (PERCIST) have been proposed as a 
new standardized method to assess radiotherapeutic response 
metabolically and quantitatively. The aim of this study was 
to evaluate therapeutic response to Stereotactic Body 
Radiotherapy for Early Stage Non-small Cell Lung Cancer, 
comparing PERCIST with the currently widely used response 
evaluation criteria in solid tumors (RECIST). 
 
Material and Methods 
Forty-nine patients with locally early Stage Non-small Cell 
Lung Cancer who received Stereotactic Body Radiotherapy 
were studied. Radiotherapeutic lesion responses were 
evaluated using CT and 18F-FDG PET according to the RECIST 
and PERCIST methods. The PET/CT scans were obtained 
before SBRT and about 3 to 6 month after SBRT. Associations 
were statistically analyzed between overall survival and 
clinicopathologic results (histology, tumor location, tumor 
size, lymphatic invasion, clinical stage, radiotherapeutic 
responses in RECIST and PERCIST).  
 
Results 
Median follow-up was 30 months. Thirteen patients had stage 
IA, 9 stage IB, 10 stage IIA, and 17 stage IIB biopsy-proven 
NSCLC. Three-year overall survival was 79.6%. CT scans 
indicated 3 regional recurrences. PET/d-chest indicated 3 
regional recurrences and distant metastasis. There was a 
significant difference in response classification between 
RECIST and PERCIST (Wilcoxon signed-rank test, P=0.0041). 
Univariate analysis showed that clinical stage, RECIST and 
PERCIST were significant factors associated with overall 
survival in this study, while by multivariate analysis PERCIST 
was the only predictor of overall survival in early NSCLC 
patients. In fact, SMD, PMD/PMR, CMR in PERCIST criteria was 
indicative of a 9.900-fold increase in the risk of overall 
survival in early NSCLC patients [RR 9.900 (95% CI 1.040, 
21.591), P=0.001]. 
 
Conclusion 
RECIST based on the anatomic size reduction rate did not 
demonstrate the correlation between therapeutic responses 
and prognosis in patients with Early Stage NSCLC receiving 
SBRT. However, PERCIST was found to be the strongest 
independent predictor of outcomes. PERCIST might be 
considered more suitable for evaluation of radiotherapeutic 
response to NSCLC than RECIST. 
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Purpose or Objective: Sarcopenia is a syndrome 
characterized by low muscle mass and low muscle function. 
Several authors reported that low skeletal muscle mass (SMM) 
was associated with decreased survival in cancer patients. 
The purpose of the present study was to retrospectively 
evaluate impact of SMM on survival and cause of death after 
stereotactic body radiotherapy (SBRT) for primary non-small 
cell lung cancer (NSCLC). 
 
Material and Methods: Of consecutive 253 patients who 
received SBRT for primary NSCLC between 2004 and 2013, 
186 patients whose abdominal CT before the treatment was 
available were enrolled into this study. SMM was evaluated 
through total psoas area (TPA) at a level of the third lumbar 
vertebra according to a method proposed by Jones et al. 
(Colorectal Dis 2015;17:O20). TPA was estimated by 
multiplying the greatest anterior/posterior and transverse 
muscle diameters and then normalizing for patient height. 
The patients were divided into two groups of SMM according 
to gender-specific thresholds for TPA. Regression analysis was 
done for the cumulative incidence function for competing 
risks of death from lung cancer and from other causes. 
Evaluated variates were SMM, age, gender, performance 
status, body mass index (BMI), Charlson comorbidity index 
(CCI), operability, modified Glasgow prognostic score 
(mGPS), recursive partitioning analysis (RPA) class, and 
histology. In multivariate analysis, step-wise selection was 
applied to identify potential factors. 
 
Results: edian TPAs were 293 and 240 mm²/m² in male and 
female, respectively, and these values were used as the 
gender-specific thresholds. Patients with lower SMM tended 
to be elderly and lean in BMI compared with the higher SMM. 
A potential median follow-up period was 55.6 months. 
Overall survival at 5 years was 41.1% and 55.9% in the lower 
and higher SMM groups, respectively (P = 0.115). Cumulative 
incidence of non-lung cancer death was significantly worse in 
the lower SMM (31.3% at 5 years compared with 9.7% in the 
higher SMM, P = 0.006). Multivariate regression analysis 
identified SMM and operability as significant factors for non-
lung cancer death (Table). Impact of SMM on lung cancer 
death was not significant with cumulative incidence of 27.6% 
and 34.4% at 5 years in the lower and higher SMM groups, 
respectively (P = 0.332). 
 
 
 
Conclusion: Low SMM is a significant risk factor for non-lung 
cancer death after SBRT for NSCLC. 
 
 
 
 
